Investment Thesis
SAB Biotherapeutics is a pre-revenue company with zero revenue and severe cash burn. Despite positive reported net income (driven by one-time gains), the company is losing $49M operationally and burning $45.7M in free cash flow annually with only $10.5M cash remaining. At current burn rates, the company faces critical funding pressure within months.
Strengths
- Zero long-term debt (Debt/Equity: 0.00x) eliminates leverage risk
- Strong current ratio of 9.46x indicates near-term liquidity from current assets
- Asset base of $172.8M provides some operational runway with $151.5M equity
Risks
- Zero revenue with -100% YoY decline indicates complete revenue loss or pre-revenue stage with failed commercialization
- Operating cash burn of -$44.8M against only $10.5M cash creates imminent solvency risk without external funding
- Positive net income of $13.3M contradicts -$49M operating loss, indicating reliance on one-time gains (non-operational) not sustainable profits
- Free cash flow negative at -$45.7M; company will deplete cash within 2-3 months at current burn rate
- EPS remains deeply negative at -0.79 despite reported positive net income, indicating significant dilution pressure
Key Metrics to Watch
- Cash runway and timeline to next funding event (critical survival metric)
- Quarterly cash burn trend and operating loss trajectory
- Revenue recognition or clinical trial progress (only path to operational viability)
Financial Metrics
Revenue
0.0
Net Income
13.3M
EPS (Diluted)
$-0.79
Free Cash Flow
-45.7M
Total Assets
172.8M
Cash
10.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
8.8%
ROA
7.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
9.46x
Quick Ratio
9.46x
Debt/Equity
0.00x
Debt/Assets
12.3%
Interest Coverage
-288.83x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T08:03:22.950032 |
Data as of: 2025-12-31 |
Powered by Claude AI